UK medicines revenue clawback rockets to 26.5% putting Life Sciences Vision at risk, says ABPI
Next year manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government (26.5% of sales), up from around £0.6bn in 2021 and £1.8bn in 2022.
Read the full articleYou might also wanna read
iRacing Subscription Price Increase (August 2026): How to Lock in Current Rates
BoxThisLap·17h ago
New York Fed Finds Tariff-Driven Price Hikes Will Stretch Past 2026
PYMNTS·2d ago
Why the government must urgently raise the NICE cost-effectiveness threshold
ABPI·2d ago
Understanding NHS medicines spending in England
ABPI·2d ago
New ORA 5 SUV lands in SA with petrol, hybrid, and EV models from R365k
htxt.co.za·2d ago
Updates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicines
ABPI·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.